Lifecore Biomedical Inc. (LFCR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lifecore Biomedical Inc. stock (LFCR) is currently trading at $4.00. Lifecore Biomedical Inc. PS ratio (Price-to-Sales) is 1.17. Analyst consensus price target for LFCR is $6.50. WallStSmart rates LFCR as Sell.
- LFCR PE ratio analysis and historical PE chart
- LFCR PS ratio (Price-to-Sales) history and trend
- LFCR intrinsic value — DCF, Graham Number, EPV models
- LFCR stock price prediction 2025 2026 2027 2028 2029 2030
- LFCR fair value vs current price
- LFCR insider transactions and insider buying
- Is LFCR undervalued or overvalued?
- Lifecore Biomedical Inc. financial analysis — revenue, earnings, cash flow
- LFCR Piotroski F-Score and Altman Z-Score
- LFCR analyst price target and Smart Rating
Lifecore Biomedical Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Lifecore Biomedical Inc. (LFCR) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Lifecore Biomedical Inc. (LFCR) Key Strengths (2)
76.41% of shares held by major funds and institutions
Paying $1.17 for every $1 of annual revenue
Supporting Valuation Data
Lifecore Biomedical Inc. (LFCR) Areas to Watch (7)
Company is destroying shareholder value
Revenue declining -3.80%, a shrinking business
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Very expensive at 192.1x book value
Micro-cap company with very limited liquidity and high volatility
Paying a premium for growth, expensive relative to earnings expansion
Supporting Valuation Data
Lifecore Biomedical Inc. (LFCR) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.17) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Profit Margin. Some valuation metrics including PEG Ratio (2.66), Price/Book (192.10) suggest expensive pricing. Growth concerns include Revenue Growth at -3.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -76.40%, Operating Margin at 8.18%, Profit Margin at -23.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -76.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -3.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LFCR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LFCR's Price-to-Sales ratio of 1.17x sits near its historical average of 1.17x (72th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 57% below its historical high of 2.75x set in Sep 2007, and 67% above its historical low of 0.7x in Nov 2011. Over the past 12 months, the PS ratio has compressed from ~2.1x as trailing revenue scaled faster than the stock price.
Compare LFCR with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Lifecore Biomedical Inc. (LFCR) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Lifecore Biomedical Inc. is in a turnaround phase, with management focused on restoring profitability. Revenue reached 129M with 4% decline year-over-year. The company is currently unprofitable, posting a -23.8% profit margin.
Key Findings
Generating 4M in free cash flow and 6M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -23.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Lifecore Biomedical Inc..
Bottom Line
Lifecore Biomedical Inc. is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Lifecore Biomedical Inc.(LFCR)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.